Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Expert Opinion on Therapeutic Targets
|
September 23, 2003
Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis
Lynn Bonham, David W Leung, Thayer White, et al.
Cancer Chemotherapy and Pharmacology
|
August 7, 2008
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
Claire F Verschraegen, Keith Skubitz, Adil Daud, et al.
Journal of Lipid Research
|
December 22, 2005
Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays
David Hollenback, Lynn Bonham, Laura Law, et al.
Molecular Cancer Therapeutics
|
October 28, 2003
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells
Michael Coon, Alexey Ball, Jeannine Pound, et al.
Cancer
|
June 18, 2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort
Tomasz P Srokowski, James E Liebmann, Manuel R Modiano, et al.
British Journal of Haematology
|
December 28, 2019
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)
Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Avery Polk, Ye Lu, Tianjiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas
John M Pagel, Christian Laugen, Lynn Bonham, et al.
British Journal of Haematology
|
April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 3, 2009
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials
Rogerio Lilenbaum, Victoria M Villaflor, Corey Langer, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Expert Opinion on Therapeutic Targets
|
September 23, 2003
Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis
Lynn Bonham, David W Leung, Thayer White, et al.
Cancer Chemotherapy and Pharmacology
|
August 7, 2008
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
Claire F Verschraegen, Keith Skubitz, Adil Daud, et al.
Journal of Lipid Research
|
December 22, 2005
Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays
David Hollenback, Lynn Bonham, Laura Law, et al.
Molecular Cancer Therapeutics
|
October 28, 2003
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells
Michael Coon, Alexey Ball, Jeannine Pound, et al.
Cancer
|
June 18, 2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort
Tomasz P Srokowski, James E Liebmann, Manuel R Modiano, et al.
British Journal of Haematology
|
December 28, 2019
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)
Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Avery Polk, Ye Lu, Tianjiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas
John M Pagel, Christian Laugen, Lynn Bonham, et al.
British Journal of Haematology
|
April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 3, 2009
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials
Rogerio Lilenbaum, Victoria M Villaflor, Corey Langer, et al.
Page
of 5